DDInter704 DDInter342
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Everolimus {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Everolimus {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Everolimus {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Certolizumab pegol
Everolimus {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Everolimus {u} (Compound) upregulates {v} (Gene) ANKRD10
ANKRD10 {u} (Gene) is downregulated by {v} (Compound) Stavudine
Stavudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Everolimus {u} (Compound) upregulates {v} (Gene) CDK5R1
CDK5R1 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fentanyl
Fentanyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Certolizumab pegol
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Certolizumab pegol
Everolimus (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Everolimus (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Everolimus (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Everolimus (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Everolimus (Compound) upregulates ANKRD10 (Gene) and ANKRD10 (Gene) is downregulated by Stavudine (Compound) and Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Everolimus (Compound) upregulates CDK5R1 (Gene) and CDK5R1 (Gene) is upregulated by Topotecan (Compound) and Topotecan may lead to a major life threatening interaction when taken with Certolizumab pegol
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol